Mechanical Complications of Acute Myocardial Infarction: a Multicenter Prospective Study
Launched by MAASTRICHT UNIVERSITY MEDICAL CENTER · Nov 5, 2024
Trial Information
Current as of August 22, 2025
Recruiting
Keywords
ClinConnect Summary
The "CAUTION Study - 2" is a clinical trial that aims to understand the outcomes of different treatments for serious heart problems that can happen after a heart attack, such as holes in the heart wall (ventricular septal defects), ruptured heart muscles (papillary muscle ruptures), and other complications. This study will recruit patients from various medical centers and will include everyone diagnosed with these complications, regardless of how they are treated—whether through surgery, less invasive procedures, or other methods.
If you or someone you know has had a heart attack and developed complications, you might be eligible to participate in this study. The trial is open to all adults aged 65 and older who meet the criteria. Participants will be closely monitored to gather detailed information about their treatment and recovery, helping doctors to better understand how to manage these serious issues in the future. This research is important because it aims to provide clearer and more reliable information about patient outcomes in today's medical practice.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • all the patients diagnosed with post-infarction mechanical complications, independently from the treatment assigned
- Exclusion Criteria:
- • patients with cardiac rupture not acute myocardial infarction related
About Maastricht University Medical Center
Maastricht University Medical Center (MUMC+) is a leading academic medical center in the Netherlands, renowned for its commitment to advancing healthcare through innovative research and education. As a prominent sponsor of clinical trials, MUMC+ integrates cutting-edge scientific inquiry with clinical practice, focusing on a wide range of medical disciplines. The center emphasizes collaboration among multidisciplinary teams, fostering an environment that promotes excellence in patient care and the translation of research findings into clinical applications. MUMC+ is dedicated to improving health outcomes and enhancing quality of life through rigorous clinical investigations and the development of novel therapeutic strategies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Varese, , Italy
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported